Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Yoshio Okano
No relevant relationships to disclose
Masahiko Ando
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Masaaki Fukuda
Stock Ownership - Chugai Pharma
Hideyuki Nakagawa
Honoraria - Chugai Pharma
Hidenori Ibata
No relevant relationships to disclose
Toshiyuki Kozuki
Honoraria - Chugai Pharma
Tateo Endo
No relevant relationships to disclose
Atsuhisa Tamura
No relevant relationships to disclose
Mitsuhiro Kamimura
Research Funding - Chugai Pharma
Kazuhiro Sakamoto
No relevant relationships to disclose
Michihiro Yoshimi
No relevant relationships to disclose
Yoshifumi Soejima
No relevant relationships to disclose
Yoshio Tomizawa
Honoraria - Chugai Pharma
Shunichi Isa
No relevant relationships to disclose
Minoru Takada
Honoraria - Chugai Pharma; Sanofi
Hideo Saka
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Akihito Kubo
Honoraria - Chugai Pharma; Sanofi
Tomoya Kawaguchi
Honoraria - Chugai Pharma; Sanofi